Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Dermata raised $5 million gross proceeds from a public offering in March 2023 -- Dermata submitted an End of Phase 2 meeting package to...
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies-- Dermata also submitted an end of phase 2 meeting...